SCHEMBL4192291

SCHEMBL4192291

COc1ccc(-c2cncc(NCc3ccoc3)c2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 3/20 0.57
ALPL P05186 5/20 0.44
KCNH2 Q12809 1/20 0.43
HPGD P15428 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
BRAF P15056 1/20 0.40
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PIK3CG P48736 1/20 0.38
CLK2 P49760 1/20 0.37
CLK3 P49761 1/20 0.37
DYRK1A Q13627 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187702 0.83 FYN (0.62) FYNALPLKCNH2HPGDCLK4
SCHEMBL4187573 0.83 FYN (0.61) FYNALPLKCNH2HPGDCLK4
SCHEMBL4199243 0.80 ALPL (0.49) FYNALPLKCNH2PDGFRBPDGFRA
SCHEMBL4194457 0.79 HSD17B1 (0.55) FYNALPLKCNH2PIK3CDPIK3CA
SCHEMBL4147320 0.78 FYN (0.76) FYNKCNH2HPGDCLK4BRAF
SCHEMBL4194118 0.78 FYN (0.72) FYNHPGDCLK4BRAFDYRK1A
SCHEMBL4139536 0.78 FYN (0.67) FYNKCNH2HPGDCLK4BRAF
SCHEMBL4192123 0.77 FYN (0.67) FYNKCNH2HPGDCLK4BRAF
SCHEMBL4199443 0.76 FYN (0.51) FYNALPLKCNH2HPGDCLK4
SCHEMBL4196785 0.74 FYN (0.62) FYNALPLKCNH2HPGDCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 FYN 3292/4885ALPL 1226/4885KCNH2 3526/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA FYN 173/4885ALPL 2140/4885KCNH2 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.